Magnetic resonance imaging of leiomyomata uteri: assessing therapy with the gonadotropin-releasing hormone agonist leuprolide.
Two cases are reported in which MRI was used to monitor the preoperative response of leiomyomata uteri to gonadotropin releasing hormone agonist therapy. The uterus was measured in the cephalocaudad, anterior-posterior, and transverse planes by MRI images. All uterine dimensions decreased in size after leuprolide therapy. One patient ultimately chose leuprolide therapy alone for control of her symptoms while a second patient had four myomas surgically removed after leuprolide therapy. MRI proved to be a good modality to monitor response to leuprolide therapy and assist in the management of these patients.
Lubich
L M
LM
Department of Radiology, University of Florida College of Medicine, Gainesville 32610.
Alderman
M G
MG
Ros
P R
PR
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007889:Leiomyoma / Q000175:diagnosis* / Q000188:drug therapy; D016729:Leuprolide; D008279:Magnetic Resonance Imaging; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D014599:Uterus / Q000473:pathology
D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide